PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för LRRK2-IN-1. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

7 hits

Bibliografisk träff 2015-03-03

Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation.

Munoz L, Kavanagh ME, Phoa AF, Heng B, Dzamko N, Chen EJ, Doddareddy MR, Guillemin GJ, Kassiou M.

Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2015.03.003

Bibliografisk träff 2014-05-06

Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.

Weygant N, Qu D, Berry WL, May R, Chandrakesan P, Owen DB, Sureban SM, Ali N, Janknecht R, Houchen CW.

Mol Cancer · research-article; journal article · DOI 10.1186/1476-4598-13-103

Bibliografisk träff 2014-04-09

Abnormal visual gain control in a Parkinson's disease model.

Afsari F, Christensen KV, Smith GP, Hentzer M, Nippe OM, Elliott CJ, Wade AR.

Hum Mol Genet · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/hmg/ddu159

Bibliografisk träff 2014-04-01

Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease.

Martin I, Kim JW, Lee BD, Kang HC, Xu JC, Jia H, Stankowski J, Kim MS, Zhong J, Kumar M, Andrabi SA, Xiong Y, Dickson DW, Wszolek ZK, Pandey A, Dawson TM, Dawson VL.

Cell · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.cell.2014.01.064

Bibliografisk träff 2012-10-12

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.

Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H, Wilson-Delfosse AL, Chen SG.

Hum Mol Genet · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1093/hmg/dds431

Bibliografisk träff 2012-08-28

Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.

Hermanson SB, Carlson CB, Riddle SM, Zhao J, Vogel KW, Nichols RJ, Bi K.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0043580

Bibliografisk träff 2011-03-06

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS.

Nat Chem Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/nchembio.538